​

Nuvation Bio (NUVB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NUVB Stock Forecast

Nuvation Bio (NUVB) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $12.40, with a high of $17.00 and a low of $10.00. This represents a 125.45% increase from the last price of $5.50.

- $4 $8 $12 $16 $20 High: $17 Avg: $12.4 Low: $10 Last Closed Price: $5.5

NUVB Stock Rating

Nuvation Bio stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

NUVB Price Target Upside V Benchmarks

TypeNameUpside
StockNuvation Bio125.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4910
Avg Price Target$13.00$12.11$11.50
Last Closing Price$5.50$5.50$5.50
Upside/Downside136.36%120.18%109.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2627---9
Dec, 2527---9
Nov, 2534---7
Oct, 2534---7
Sep, 2534---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026Truist Financial$13.00$5.66129.68%136.36%
Jan 21, 2026Leonid TimashevRBC Capital$12.00$6.0199.67%118.18%
Jan 12, 2026H.C. Wainwright$17.00$6.52160.74%209.09%
Jan 07, 2026Michael YeeUBS$10.00$8.4917.79%81.82%
Dec 11, 2025H.C. Wainwright$18.00$7.89128.14%227.27%
Dec 01, 2025Robert BurnsH.C. Wainwright$10.00$8.0424.38%81.82%
Nov 24, 2025Truist Financial$11.00$6.9957.37%100.00%
Nov 20, 2025JMP Securities$10.00$7.2937.17%81.82%
Nov 04, 2025JMP Securities$8.00$5.1754.74%45.45%
Apr 23, 2025Silvan TuerkcanJMP Securities$6.00$2.08188.46%9.09%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 21, 2026RBC CapitalOutperformOutperformhold
Jan 07, 2026UBSNeutralinitialise
Dec 01, 2025H.C. WainwrightBuyBuyhold
Nov 19, 2025B. RileyBuyinitialise
Nov 04, 2025CitigroupOutperformOutperformhold
Nov 04, 2025CitigroupMarket OutperformMarket Outperformhold
Sep 30, 2025JefferiesBuyBuyinitialise
Apr 23, 2025CitigroupOutperforminitialise
Mar 03, 2025RBC CapitalOutperformOutperformhold
Jan 07, 2025RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.35$-2.11----
Avg Forecast$-0.38$-2.12$-0.59$-0.51$-0.37$-0.12
High Forecast$-0.38$-2.07$-0.55$-0.50$-0.27$-0.11
Low Forecast$-0.38$-2.25$-0.62$-0.51$-0.47$-0.12
Surprise %-7.89%-0.47%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$7.87M----
Avg Forecast-$2.19M$10.29M$59.25M$178.14M$315.64M
High Forecast-$2.22M$10.41M$59.95M$180.24M$319.36M
Low Forecast-$2.18M$10.15M$58.49M$175.85M$311.58M
Surprise %-259.94%----

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-75.80M$-567.94M----
Avg Forecast$-83.01M$-471.96M$-128.04M$-110.53M$-80.99M$-25.17M
High Forecast$-82.57M$-452.47M$-120.04M$-108.56M$-58.54M$-24.75M
Low Forecast$-83.46M$-491.44M$-136.05M$-112.51M$-103.43M$-25.56M
Surprise %-8.69%20.34%----

NUVB Forecast FAQ

Is Nuvation Bio stock a buy?

Nuvation Bio stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nuvation Bio is a favorable investment for most analysts.

What is Nuvation Bio's price target?

Nuvation Bio's price target, set by 8 Wall Street analysts, averages $12.4 over the next 12 months. The price target range spans from $10 at the low end to $17 at the high end, suggesting a potential 125.45% change from the previous closing price of $5.5.

How does Nuvation Bio stock forecast compare to its benchmarks?

Nuvation Bio's stock forecast shows a 125.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nuvation Bio over the past three months?

  • January 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Nuvation Bio’s EPS forecast?

Nuvation Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.59, marking a -72.04% decrease from the reported $-2.11 in 2024. Estimates for the following years are $-0.51 in 2026, $-0.37 in 2027, and $-0.12 in 2028.

What is Nuvation Bio’s revenue forecast?

Nuvation Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $10.29M, reflecting a 30.65% increase from the reported $7.87M in 2024. The forecast for 2026 is $59.25M, followed by $178.14M for 2027, and $315.64M for 2028.

What is Nuvation Bio’s net income forecast?

Nuvation Bio's net income forecast for the fiscal year ending in December 2025 stands at $-128M, representing a -77.45% decrease from the reported $-568M in 2024. Projections indicate $-111M in 2026, $-80.986M in 2027, and $-25.171M in 2028.